+

WO2004048352A3 - Inhibiteur de la dpp-iv - Google Patents

Inhibiteur de la dpp-iv Download PDF

Info

Publication number
WO2004048352A3
WO2004048352A3 PCT/JP2003/015061 JP0315061W WO2004048352A3 WO 2004048352 A3 WO2004048352 A3 WO 2004048352A3 JP 0315061 W JP0315061 W JP 0315061W WO 2004048352 A3 WO2004048352 A3 WO 2004048352A3
Authority
WO
WIPO (PCT)
Prior art keywords
dpp
cyanopyrrolidines
analogues
inhibitors
formula
Prior art date
Application number
PCT/JP2003/015061
Other languages
English (en)
Other versions
WO2004048352A2 (fr
Inventor
Ichiro Shima
Toshio Kurosaki
Original Assignee
Fujisawa Pharmaceutical Co
Ichiro Shima
Toshio Kurosaki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co, Ichiro Shima, Toshio Kurosaki filed Critical Fujisawa Pharmaceutical Co
Priority to AU2003283832A priority Critical patent/AU2003283832A1/en
Publication of WO2004048352A2 publication Critical patent/WO2004048352A2/fr
Publication of WO2004048352A3 publication Critical patent/WO2004048352A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)

Abstract

L'invention porte sur un composé (ou ses sels pharmacocompatibles) de formule (I) dans laquelle: X est CH2, O ou S; R2 est hydrogène, etc, et R1 est un fragment de formule (II) dans laquelle: R3 est alkyle inférieur, etc; et m est un entier de 1 à 3. Le composé de formule (I), qui inhibe l'activité de la DPP-IV s'avèrent utiles pour le traitement d'états médiés par la DPP-IV, tels que le diabète non insulino-dépendant.
PCT/JP2003/015061 2002-11-27 2003-11-26 Inhibiteur de la dpp-iv WO2004048352A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003283832A AU2003283832A1 (en) 2002-11-27 2003-11-26 2-cyanopyrrolidines and their analogues as dpp-iv inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2002952946A AU2002952946A0 (en) 2002-11-27 2002-11-27 Dpp-iv inhibitor
AU2002-952946 2002-11-27

Publications (2)

Publication Number Publication Date
WO2004048352A2 WO2004048352A2 (fr) 2004-06-10
WO2004048352A3 true WO2004048352A3 (fr) 2004-07-08

Family

ID=29741559

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/015061 WO2004048352A2 (fr) 2002-11-27 2003-11-26 Inhibiteur de la dpp-iv

Country Status (2)

Country Link
AU (1) AU2002952946A0 (fr)
WO (1) WO2004048352A2 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470700B2 (en) 2003-08-13 2008-12-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7553861B2 (en) 2005-04-22 2009-06-30 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
US7842707B2 (en) 2004-07-23 2010-11-30 Nuada, Llc Peptidase inhibitors
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1625122A1 (fr) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Inhibiteurs de dipeptidyl peptidase
CN101360723A (zh) 2005-09-16 2009-02-04 武田药品工业株式会社 制备嘧啶二酮衍生物的方法
GB0526291D0 (en) 2005-12-23 2006-02-01 Prosidion Ltd Therapeutic method
WO2007112347A1 (fr) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Inhibiteurs de la dipeptidyl peptidase
MX2008013130A (es) 2006-04-12 2008-11-19 Probiodrug Ag Inhibidores de enzima.
EP2089383B1 (fr) 2006-11-09 2015-09-16 Probiodrug AG Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
ATE554085T1 (de) 2006-11-30 2012-05-15 Probiodrug Ag Neue inhibitoren von glutaminylcyclase
DK2142514T3 (da) 2007-04-18 2015-03-23 Probiodrug Ag Thioureaderivater som glutaminylcyclase-inhibitorer
KR20200118243A (ko) * 2008-08-06 2020-10-14 베링거 인겔하임 인터내셔날 게엠베하 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
US8486940B2 (en) 2009-09-11 2013-07-16 Probiodrug Ag Inhibitors
ES2586231T3 (es) 2010-03-03 2016-10-13 Probiodrug Ag Inhibidores de glutaminil ciclasa
EA022420B1 (ru) 2010-03-10 2015-12-30 Пробиодруг Аг Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5)
JP5945532B2 (ja) 2010-04-21 2016-07-05 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
WO2012170702A1 (fr) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci
JP6307989B2 (ja) * 2014-04-02 2018-04-11 住友化学株式会社 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419683A1 (fr) * 1989-04-13 1991-04-03 Japan Tobacco Inc. Nouveaux derives aminoacides possedant une activite d'inhibiteur de la prolylendopeptidase
WO2001096295A2 (fr) * 2000-06-13 2001-12-20 Novartis Ag Composes organiques
WO2002076450A1 (fr) * 2001-03-27 2002-10-03 Merck & Co., Inc. Inhibiteurs de peptidase dipeptidyl destines au traitement ou a la prevention du diabete
WO2002083109A1 (fr) * 2001-04-11 2002-10-24 Ferring Bv Traitement du diabete de type 2 a l'aide d'inhibiteurs de dipeptidylpeptidase iv

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0419683A1 (fr) * 1989-04-13 1991-04-03 Japan Tobacco Inc. Nouveaux derives aminoacides possedant une activite d'inhibiteur de la prolylendopeptidase
WO2001096295A2 (fr) * 2000-06-13 2001-12-20 Novartis Ag Composes organiques
WO2002076450A1 (fr) * 2001-03-27 2002-10-03 Merck & Co., Inc. Inhibiteurs de peptidase dipeptidyl destines au traitement ou a la prevention du diabete
WO2002083109A1 (fr) * 2001-04-11 2002-10-24 Ferring Bv Traitement du diabete de type 2 a l'aide d'inhibiteurs de dipeptidylpeptidase iv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NOVARTIS A G: "NOVEL N-SUBSTITUTED-2-CYANOPYRROLIDINES AS POTENT INHIBITORS OF DIPEPTIDYL PEPTIDASE IV IN THE TREATMENT OF NON-INSULIN-DEPENDENT DIABETES MELLITUS", EXPERT OPINION ON THERAPEUTIC PATENTS, ASHLEY PUBLICATIONS, GB, vol. 10, no. 12, December 2000 (2000-12-01), pages 1937 - 1942, XP001019155, ISSN: 1354-3776 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550590B2 (en) 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7470700B2 (en) 2003-08-13 2008-12-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7579357B2 (en) 2003-08-13 2009-08-25 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7842707B2 (en) 2004-07-23 2010-11-30 Nuada, Llc Peptidase inhibitors
US7553861B2 (en) 2005-04-22 2009-06-30 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
US8906901B2 (en) 2005-09-14 2014-12-09 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors

Also Published As

Publication number Publication date
AU2002952946A0 (en) 2002-12-12
WO2004048352A2 (fr) 2004-06-10

Similar Documents

Publication Publication Date Title
WO2004048352A3 (fr) Inhibiteur de la dpp-iv
WO2005042533A3 (fr) Compose 2-cyanopyrrolidinecarboxamide
CA2318349A1 (fr) Oestrone sulfamate inhibant l'oestrone sulfatase, compositions pharmaceutiques associees et methodes d'utilisation
AP2002002637A0 (en) Novel piperazine
WO2004058679A3 (fr) Ligands d'adenine nucleotide translocase (ant) et compositions et methodes associees
DE69831868D1 (en) Antithrombosemittel
IL133623A0 (en) Antithrombotic agents
MXPA03011981A (es) 3-fluoruro-pirrolidinas como agentes antidiabeticos.
CA2328780A1 (fr) Dihydropyrimidines
GB0019359D0 (en) Novel guanidines
MY140680A (en) Hepatitis c virus inhibitors
ZA200201831B (en) Quinazoline derivatives.
CA2203237A1 (fr) Derives d'aminotetrazole utiles en tant qu'inhibiteurs de la monoxyde d'azote synthetase
RS101304A (sr) Indolni, azaindolni i srodni heterociklični 4-alkenil piperidinski amidi
DE602005013931D1 (fr)
IS7482A (is) Fjölhringa efnasambönd sem sterk alfa2-adrenóviðtakamótlyf
HU9301155D0 (en) Methods for producing steroide derivatives and for their application in medical treatment
AU2267495A (en) Benzamide derivatives as vasopressin antagonists
GEP20074045B (en) (4-phenyl) piperidin-3-yl-phenylcarboxylate derivatives and related compounds as beta-secretase inhibitors for the treatment of alzheimer's disease
SE8107273L (sv) 2-oxoazetidinderivat, sett att framstella democh anvendning derav
EP1550651A4 (fr) Derive glycerol
DE60114640D1 (en) Antithrombosemittel
MXPA04007643A (es) Inhibidores de la adhesion celular mediada por integrina alb2.
NO20062307L (no) Spirofuropyridinarylderivater
WO2004058683A3 (fr) Ligands d'adenine nucleotide translocase (ant) et compositions et methodes associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载